NeoGenomics (NEO)
(Delayed Data from NSDQ)
$5.16 USD
+0.32 (6.61%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $5.17 +0.01 (0.19%) 7:58 PM ET
4-Sell of 5 4
C Value A Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NEO 5.16 +0.32(6.61%)
Will NEO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NEO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NEO
Down 29.2% in 4 Weeks, Here's Why NeoGenomics (NEO) Looks Ripe for a Turnaround
NeoGenomics (NEO) Meets Q2 Earnings Estimates
NEO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for
NeoGenomics (NEO) Reports Break-Even Earnings for Q1
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for
Other News for NEO
NeoGenomics (NEO) Stock Price Target Lowered by Morgan Stanley | NEO Stock News
NeoGenomics (NEO) Price Target Cut by Morgan Stanley amid Revenue Challenges
Peloton upgraded, Booking downgraded: Wall Street's top analyst calls
NeoGenomics price target lowered by $2 at Morgan Stanley, here's why
NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with ...